DF/HCC Breast & Gynecologic Cancer Symposium

On Friday, March 29, 2024 the Susan F. Smith Center for Women’s Cancers and the Breast and Gynecologic Programs in the DF/HCC will sponsor a day-long symposium to highlight breast and gynecologic cancer research at Harvard.

We invite all DF/HCC researchers who are doing work in breast and gynecologic cancers, including fellows, post-docs, and junior faculty to attend and to submit abstracts.

ACTION REQUIRED:

Register/Submit an Abstract

2024 Agenda

March 29, 2024

Joseph B. Martin Conference Center

Harvard Medical School
77 Avenue Louis Pasteur
Boston MA, 02115

DOWNLOAD AGENDA

7:15 am	Sign-In, Continental Breakfast, Poster Set-Up
8:00 am	Welcome/Purpose of Symposium Susan F. Smith Center Leaders
8:10 am	J. Dirk Iglehart, M.D., Visiting Scholar Lecture *Harnessing omics and AI for precision breast oncology* Christina Curtis, PhD, MSc RZ Cao Professor of Medicine, Genetics & Biomedical Data Science Director AI and Cancer Genomics Director, Breast Cancer Translational Research Investigator, Chan Zuckerberg Biohub Stanford University (35-40 min talk, 10 mins questions)
9:00 am	SESSION I:Genomics Chair: Gerburg Wulf
9:00 – 9:45 am	3 oral presentations (10 mins each; 5 mins questions) Abstract #1 Okoh Frimpong: Chemoproteomic Evaluation of PROTACs Targeting Estrogen Receptor Alpha in ER+ Breast Cancer Abstract #4 Zheqi Li: KDM4C histone demethylase prevents histone cleavage in breast cancer Abstract #9 Jessica St. Laurent: Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in endometrioid carcinomas
9:45 am	POSTER SESSION 9:45 am – 10:30 am – Open Posters
10:30 am	SESSION II: Risk, Prevention & Disparities/Clinical Chair: Sara Tolaney
10:30 – 11:15 am	3 oral presentations (10 mins each; 5 mins questions) Abstract #12 Haohui Duan: BRCA2 haploinsufficiency induces P53 degradation in primary mammary epithelial cells – a crucial early event in breast tumor promotion Abstract #18 Jennifer Mongiovi: Associations between intrauterine device use and ovarian cancer risk among 11 population-based case-control studies Abstract #21 Xingping Qin: Safely targeting endogenous and therapy-enhanced BCL-XL dependence in ovarian cancer using the PROTAC DT2216
11:15 am	M. Patricia Cronin Memorial Lecture *Why listening to women matters in ovarian cancer research* Sarah M. Temkin, M.D. Associate Director for Clinical Research Office of Research on Women’s Health Office of the Director, NIH (35-40 min talk, 10 mins questions)
12:05 pm	Lunch and Open Posters 12:05 – 1:15pm
1:15 pm	SESSION III: Drug Resistance/Animal Models Chair: Patricia Donahoe
1:15 – 2:15 pm	4 oral presentations (10 mins each; 5 mins questions) Abstract #30 Carman Li: Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer Abstract #32 Yusuke Matoba: Targeting Bcl-XL is a potential novel therapy for uterine serous cancer Abstract #35 Ramya Ravindranathan: PARG inhibitor sensitivity is correlated with accumulation of single strand DNA gaps in preclinical models of ovarian cancer Abstract #40 Ting Liu: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC.
2:15 pm	SESSION IV: Tumor Microenvironment/Immunology Chair: Jean Zhao
2:15 – 3:00 pm	3 oral presentations (10 mins each; 5 mins questions) Abstract #41 Sara Busatto: Breast cancer-derived extracellular vesicles modulate the endocytic metabolism and morphodynamics of the endothelial cells of the blood-brain barrier Abstract #43 Maeva Chauvin: Targeting Follistatin-like 3 to reverse immunotherapy resistance in ovarian cancer Abstract #46 Adam Nelson: Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC)
3:00 pm	Announcement of Awards and Adjourn